Recent 8-K filings for SGMO

• May 14, 2026, 4:02 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB

  Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.

• April 29, 2026, 7:59 PM ET regulatory materiality 0.75 negative item 8.01

  Sangamo Therapeutics receives Nasdaq delisting notice; trading to be suspended May 5, 2026

  Nasdaq staff determined to delist SGMO due to failure to meet minimum bid price requirement.

• March 30, 2026, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Sangamo 2025 net loss $122.9M; cash only $20.9M; Fabry BLA rolling submission ongoing

  Consolidated 2025 net loss $122.9M ($0.44/sh); Q4 loss $37.4M ($0.11/sh).

• February 4, 2026, 6:59 PM ET other material materiality 0.75 negative item 1.01item 3.02item 9.01 ◈ Material Agreements

  Sangamo raises ~$25M in underwritten offering of common stock and warrants; amends prior warrants

  Offering of 35.19M shares + pre-funded warrants for 17.79M shares, each with a purchase warrant for 52.98M shares.

• February 3, 2026, 6:59 PM ET other material materiality 0.85 negative item 2.02item 5.02

  Sangamo reports ~$20.9M preliminary cash; CFO terminates, interim CFO appointed

  Preliminary cash and cash equivalents as of Dec 31, 2025: ~$20.9 million (unaudited, subject to change).

• February 3, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 8.01

  Sangamo: ST-920 Phase 1/2 data positive; FDA agrees to Accelerated Approval path

  FDA agreed Phase 1/2 STAAR data can support Accelerated Approval using eGFR slope at 52 weeks; rolling BLA started Dec 2025.

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Sangamo Q3 net loss $34.9M, revenue $0.6M; advancing Fabry BLA and pain trial enrollment

  Q3 2025 consolidated net loss $34.9M ($0.11/sh) vs net income $10.7M ($0.04/sh) in prior year.

• October 29, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices ×2

  Sangamo gets Nasdaq extension to April 27, 2026 to meet $1.00 bid price

  Received 180-day extension from Nasdaq until April 27, 2026 to regain minimum bid price compliance.

• September 30, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

  Sangamo CFO Duraibabu resigns effective Oct 1, stays part-time; Jain new principal accounting officer

  CFO Duraibabu resigns effective Oct 1, 2025; transitions to part-time principal financial officer role.

• September 11, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

  Sangamo Therapeutics CFO Prathyusha Duraibabu resigns, effective Oct 1, 2025

  Duraibabu resigns to become senior leader at a private AI company; not due to any disagreement with Sangamo.

• September 4, 2025, 7:59 PM ET other material materiality 0.80 neutral item 8.01

  Sangamo reports positive eGFR slopes in Phase 1/2 STAAR gene therapy for Fabry; BLA planned Q1 2026

  Mean annualized eGFR slope of +1.965 mL/min/1.73m2/yr (95% CI: -0.153, 4.083) at 52 weeks across 32 patients.

• August 7, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Sangamo reports positive Fabry gene therapy data, Q2 net loss narrows to $20M

  Positive topline from registrational STAAR study: mean annualized eGFR slope +1.965 at 52 weeks across all 32 dosed Fabry patients; FDA agrees as primary basis for accelerated approval.

• June 24, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01

  Sangamo reports positive Phase 1/2 data for Fabry gene therapy ST-920; BLA plan Q1 2026

  Mean annualized eGFR slope +1.965 at 52 weeks across 32 patients; +1.747 at 104 weeks for 19 patients.

• May 13, 2025, 7:59 PM ET other materiality 0.65 neutral item 8.01item 9.01

  Sangamo Therapeutics raises ~$23M in underwritten public offering of common stock and warrants

  Offering of 12.2M shares and pre-funded warrants for 34.4M shares, each with accompanying purchase warrant, at $0.50 unit price.

• May 6, 2025, 7:59 PM ET other material materiality 0.75 negative item 3.01

  Sangamo receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure

  On April 30, 2025, Nasdaq notified Sangamo that its stock closed below $1.00 for 30 consecutive business days.

• March 17, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Sangamo FY2024 net loss $97.9M; FDA clears ST-503 IND; Fabry BLA path to Accelerated Approval

  FY2024 net loss $97.9M ($0.49/share) vs $257.8M ($1.48) in 2023; revenue $57.8M vs $176.2M.

• February 6, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01

  Sangamo reports updated Phase 1/2 STAAR data for ST-920; eGFR slope +3.061; FDA Accelerated Approval path confirmed

  33 patients treated; gene therapy ST-920 generally well-tolerated; no deaths or discontinuations.

• December 30, 2024, 6:59 PM ET other material materiality 0.85 negative item 1.02

  Pfizer terminates hemophilia A gene therapy deal with Sangamo; milestone payments lost

  Pfizer notified Sangamo of termination for convenience effective April 21, 2025; no BLA or MAA to be submitted.

• December 10, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Sangamo: Phase 3 hemophilia A gene therapy succeeds; share authorization suit resolved

  Phase 3 AFFINE trial met primary endpoint: mean ABRtotal reduced from 4.73 (prophylaxis) to 1.24 post infusion (p=0.004).

• November 12, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Sangamo posts Q3 net income $10.7M; FDA clears Accelerated Approval path for Fabry gene therapy ST-920

  Net income $10.7M ($0.04 diluted EPS) vs net loss $104.2M ($0.59 loss) in Q3 2023.

• October 4, 2024, 7:59 PM ET litigation materiality 0.70 negative item 7.01item 9.01

  Sangamo files to validate share increase; stockholder challenge; hearing Dec 12

  Stockholder lawsuit claims wrong voting standard for share increase; company seeks validation.

• August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Sangamo posts Q2 net loss $0.18/sh, cash $27.8M; signs Genentech deal for up to $1.9B

  Signed global license with Genentech for zinc finger repressors targeting tau and STAC-BBB capsid; $50M near-term, up to $1.9B milestones plus royalties.

• July 24, 2024, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Sangamo Phase 3 hemophilia A gene therapy meets primary endpoint with superiority over prophylaxis

  AFFINE trial achieved superiority on total ABR (1.24 vs 4.73, p=0.0040) compared to FVIII prophylaxis.

• May 9, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Sangamo Q1 net loss $49.1M on revenue collapse to $0.5M from $158M; cash runway only into Q3 2024

  Net loss of $49.1M vs net income $21.1M YoY; diluted EPS -$0.27 vs +$0.12.

• April 30, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Sangamo receives Nasdaq deficiency notice for bid price below $1 per share

  Notice received April 24, 2024; stock closed below $1 for 30 consecutive business days.

• March 25, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Sangamo Therapeutics announces $24M registered direct offering of common stock and warrants

  Offering includes 24.8M shares, 3.8M pre-funded warrants, and 28.6M purchase warrants at $0.84/unit.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event other_material

8 positive 12 negative 8 neutral

source · SGMO on sec.gov